ReviewCureus2025
Artificial Intelligence in Radiology: Transforming Cancer Detection and Diagnosis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is increasingly integral to radiological oncology, where it supports complex image interpretation, quantitative tumor analysis, and clinical decision-making. This review synthesizes state-of-the-art developments in AI applications across major cancer types: breast, lung, prostate, brain, gastrointestinal, and metastatic disease, focusing on deep learning, radiomics, and radiogenomics frameworks. These technologies have demonstrated substantial improvements in lesion detection, segmentation accuracy, risk prediction, and molecular phenotype inference, with performance metrics that approach or surpass those of experienced radiologists. The review also explores AI integration with diverse imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), and digital mammography, while examining AI's impact on workflow triage, report standardization, and radiologist efficiency. Despite these advancements, key challenges persist, including limited model generalizability across populations and institutions, data silos, regulatory uncertainty, and the need for explainable AI outputs in clinical contexts. Emphasis is placed on enabling strategies such as federated learning, multicenter data harmonization, post-deployment monitoring, and integration into picture archiving and communication system/radiology information system (PACS/RIS) infrastructure. The article provides a critical evaluation of the current landscape while outlining strategic directions for safe, equitable, and effective implementation. Rather than replacing radiologists, AI is emerging as a collaborative partner shaping a future of data-driven, personalized oncologic imaging that aligns with precision medicine goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.